\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Corporate Presentation

Please select from the documents below
............................................................................................................................ 

Cardiff Oncology Investor Presentation - January 18th, 2022